Accurate diagnosis of many neurological conditions, especially movement disorders is difficult to make in the initial stages. Hence management in such cases is delayed. Many people mistakenly attribute the first symptoms of PS, such as PD, to the normal aging process, and many have misconceptions about diagnosis. DaTscan is helpful in diagnosing PS.

Team@CMHF

Clinical exams alone, particularly early in the disease, are often inconclusive and can result in misdiagnosis. DaTscan (Ioflupane I 123 Injection) is an FDA-approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with suspected PS. The agent may enable appropriate management for adult patients who have signs or symptoms of PS, by aiding with diagnosis.

DaTscan is an adjunct to other diagnostic evaluations to help differentiate essential tremor from tremors due to PS. The effectiveness of DaTscan as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established and DaTscan was not designed to differentiate between different forms of PS.
However, DaTscan is an additional diagnostic imaging tool that may help expedite an accurate diagnosis, which could improve disease management and ensure the use of appropriate medications.

Reference: http://www.healthimaging.com/index.php?option=com_articles&article=28500&publication=10&view=portals